{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:52Z","timestamp":1792652152906,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas | Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ASP4345, a novel dopamine D<jats:sub>1<\/jats:sub> receptor positive allosteric modulator, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS). This phase 1 multiple ascending-dose study (NCT02720263) assessed the safety, tolerability, and pharmacodynamics of ASP4345 in patients with schizophrenia\/schizoaffective disorder. Pharmacodynamic assessments were Cogstate cognitive tests and electrophysiological biomarkers, including gamma-band power and phase synchronization in response to 40-Hz auditory steady-state stimulation, as well as mismatch negativity (MMN) and P3a event-related potentials. The sample size determination was based on standard practice in assessing safety and tolerability of a new chemical entity. Data were summarized by conversion of this data into effect sizes using descriptive and inferential statistics. A total of 36 randomized patients received ASP4345 (3, 15, 50, and 150\u2009mg; <jats:italic>n<\/jats:italic>\u2009=\u20099 each dose) and 12 patients received placebo. Patients in the ASP4345 group experienced 73 treatment-emergent adverse events (TEAEs) and 34 TEAEs were reported for the placebo group. The most common TEAEs were headache and somnolence and nearly all TEAEs were mild in severity. No changes in mood or self-reports of suicidal ideation\/behavior were observed. Improvements in performance on cognitive tests were noted, which suggests a potential improvement in psychomotor function and visual attention. Furthermore, positive changes in neurophysiological biomarkers (auditory steady-state response [ASSR] and MMN) suggest improvement in information processing. The findings need to be confirmed in studies with a larger patient population. Nonetheless, the trends in safety and pharmacodynamic data support further clinical development of ASP4345 for the treatment of CIAS.<\/jats:p>","DOI":"10.1038\/s41386-020-00908-0","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T19:02:37Z","timestamp":1605639757000},"page":"1145-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia"],"prefix":"10.1038","volume":"46","author":[{"given":"Amit","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruishan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Gertsik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Maruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Uz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J.","family":"Marek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"908_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.112679","volume":"205","author":"TJ Brozoski","year":"1979","unstructured":"Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 1979;205:929\u201332.","journal-title":"Science"},{"key":"908_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","volume":"68","author":"ES Bromberg-Martin","year":"2010","unstructured":"Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron. 2010;68:815\u201334.","journal-title":"Neuron."},{"key":"908_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.neuro.28.061604.135722","volume":"30","author":"W Schultz","year":"2007","unstructured":"Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci. 2007;30:259\u201388.","journal-title":"Annu Rev Neurosci"},{"key":"908_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","volume":"174","author":"PS Goldman-Rakic","year":"2004","unstructured":"Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology. 2004;174:3\u201316.","journal-title":"Psychopharmacology."},{"key":"908_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.biopsych.2015.12.028","volume":"81","author":"AF Arnsten","year":"2017","unstructured":"Arnsten AF, Girgis RR, Gray DL, Mailman RB. Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biol Psychiatry. 2017;81:67\u201377.","journal-title":"Biol Psychiatry"},{"key":"908_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.tics.2018.12.006","volume":"23","author":"T Ott","year":"2019","unstructured":"Ott T, Nieder A. Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci. 2019;23:213\u201334.","journal-title":"Trends Cogn Sci"},{"issue":"Suppl 9","key":"908_CR7","first-page":"9","volume":"67","author":"CA Tamminga","year":"2006","unstructured":"Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry. 2006;67 Suppl 9:9\u201313.","journal-title":"J Clin Psychiatry."},{"key":"908_CR8","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1177\/0269881111409265","volume":"26","author":"A Abi-Dargham","year":"2012","unstructured":"Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, et al. Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112. J Psychopharmacol. 2012;26:794\u2013805.","journal-title":"J Psychopharmacol"},{"key":"908_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1021\/acs.jmedchem.8b01767","volume":"62","author":"A Hall","year":"2019","unstructured":"Hall A, Provins L, Valade A. Novel strategies to activate the dopamine D(1) receptor: recent advances in orthosteric agonism and positive allosteric modulation. J Med Chem. 2019;62:128\u201340.","journal-title":"J Med Chem"},{"key":"908_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1124\/mol.118.113175","volume":"94","author":"KD Luderman","year":"2018","unstructured":"Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, et al. Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites. Mol Pharmacol. 2018;94:1197\u2013209.","journal-title":"Mol Pharmacol"},{"key":"908_CR11","first-page":"339","volume":"21","author":"PJ Blanchet","year":"1998","unstructured":"Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, et al. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21:339\u201343.","journal-title":"Clin Neuropharmacol"},{"key":"908_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF02252620","volume":"6","author":"MS Starr","year":"1993","unstructured":"Starr MS, Starr BS. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J Neural Transm Park Dis Dement Sect. 1993;6:27\u201334.","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"908_CR13","doi-asserted-by":"publisher","unstructured":"Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, et al. Pharmacokinetics of ASP4345 from single ascending-dose and multiple ascending-dose phase I studies. Clin Pharmacokinet. 2020. https:\/\/doi.org\/10.1007\/s40262-020-00911-0.","DOI":"10.1007\/s40262-020-00911-0"},{"key":"908_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0269881116636120","volume":"30","author":"RR Girgis","year":"2016","unstructured":"Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol. 2016;30:428\u201335.","journal-title":"J Psychopharmacol"},{"key":"908_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.schres.2010.09.012","volume":"124","author":"RH Pietrzak","year":"2010","unstructured":"Pietrzak RH, Snyder PJ, Maruff P. Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophr Res. 2010;124:176\u201382.","journal-title":"Schizophr Res"},{"key":"908_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/hup.1118","volume":"25","author":"RH Pietrzak","year":"2010","unstructured":"Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol. 2010;25:353\u20138.","journal-title":"Hum Psychopharmacol"},{"key":"908_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.biopsych.2012.01.016","volume":"71","author":"K Kirihara","year":"2012","unstructured":"Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012;71:873\u201380.","journal-title":"Biol Psychiatry"},{"key":"908_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.biopsych.2006.03.055","volume":"60","author":"GA Light","year":"2006","unstructured":"Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, et al. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006;60:1231\u201340.","journal-title":"Biol Psychiatry"},{"key":"908_CR19","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1038\/npp.2017.81","volume":"42","author":"GA Light","year":"2017","unstructured":"Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow NR. Single-dose memantine improves cortical oscillatory response dynamics in patients with schizophrenia. Neuropsychopharmacology. 2017;42:2633\u20139.","journal-title":"Neuropsychopharmacology."},{"key":"908_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.nicl.2014.09.006","volume":"6","author":"AJ Rissling","year":"2014","unstructured":"Rissling AJ, Miyakoshi M, Sugar CA, Braff DL, Makeig S, Light GA. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. NeuroImage Clin. 2014;6:424\u201337.","journal-title":"NeuroImage Clin"},{"key":"908_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fpsyt.2020.00012","volume":"11","author":"TR Seech","year":"2020","unstructured":"Seech TR, Funke ME, Sharp RF, Light GA, Blacker KJ. Impaired sensory processing during low-oxygen exposure: a noninvasive approach to detecting changes in cognitive states. Front Psychiatry. 2020;11:12.","journal-title":"Front Psychiatry"},{"key":"908_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/npp.2015.162","volume":"41","author":"NR Swerdlow","year":"2016","unstructured":"Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis. Neuropsychopharmacology. 2016;41:419\u201330.","journal-title":"Neuropsychopharmacology."},{"key":"908_CR23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/0269881119855302","volume":"33","author":"E Arce","year":"2019","unstructured":"Arce E, Balice-Gordon R, Duvvuri S, Naylor M, Xie Z, Harel B, et al. A novel approach to evaluate the pharmacodynamics of a selective dopamine D1\/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia. J Psychopharmacol. 2019;33:1237\u201347.","journal-title":"J Psychopharmacol"},{"key":"908_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/npp.2014.192","volume":"40","author":"DR Rosell","year":"2015","unstructured":"Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, et al. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015;40:446\u201353.","journal-title":"Neuropsychopharmacology."},{"key":"908_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41386-019-0519-0","volume":"45","author":"GA Light","year":"2020","unstructured":"Light GA, Swerdlow NR. Selection criteria for neurophysiologic biomarkers to accelerate the pace of CNS therapeutic development. Neuropsychopharmacology. 2020;45:237\u20138.","journal-title":"Neuropsychopharmacology."},{"key":"908_CR26","doi-asserted-by":"publisher","unstructured":"Light GA, Joshi YB, Molina JL, Bhakta SG, Nungaray JA, Cardoso L, et al. Neurophysiological biomarkers for schizophrenia therapeutics. Biomark Neuropsychiatry. 2020;2. https:\/\/doi.org\/10.1016\/j.bionps.2020.100012.","DOI":"10.1016\/j.bionps.2020.100012"},{"key":"908_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-803161-2.00012-6","volume":"29","author":"YB Joshi","year":"2019","unstructured":"Joshi YB, Tarasenko M, Light GA. Applications of neurophysiological biomarkers in CNS drug development: focus on psychoses. Handb Behav Neurosci. 2019;29:191\u20138.","journal-title":"Handb Behav Neurosci"},{"key":"908_CR28","doi-asserted-by":"publisher","unstructured":"Sahin M, Jones SR, Sweeney JA, Berry-Kravis E, Connors BW, Ewen JB, et al. Discovering translational biomarkers in neurodevelopmental disorders. Nat Rev Drug Discov. 2018. https:\/\/doi.org\/10.1038\/d41573-018-00010-7.","DOI":"10.1038\/d41573-018-00010-7"},{"key":"908_CR29","doi-asserted-by":"publisher","first-page":"e39434","DOI":"10.1371\/journal.pone.0039434","volume":"7","author":"GA Light","year":"2012","unstructured":"Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, et al. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PloS ONE. 2012;7:e39434.","journal-title":"PloS ONE"},{"key":"908_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jamapsychiatry.2016.2980","volume":"74","author":"ML Thomas","year":"2017","unstructured":"Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, et al. Modeling deficits from early auditory information processing to psychosocial functioning in schizophrenia. JAMA Psychiatry. 2017;74:37\u201346.","journal-title":"JAMA Psychiatry"},{"key":"908_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/archpsyc.62.2.127","volume":"62","author":"GA Light","year":"2005","unstructured":"Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005;62:127\u201336.","journal-title":"Arch Gen Psychiatry"},{"key":"908_CR32","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1176\/appi.ajp.162.9.1741","volume":"162","author":"GA Light","year":"2005","unstructured":"Light GA, Braff DL. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005;162:1741\u20133.","journal-title":"Am J Psychiatry"},{"key":"908_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1017\/S1355617707070816","volume":"13","author":"M Kiang","year":"2007","unstructured":"Kiang M, Light GA, Prugh J, Coulson S, Braff DL, Kutas M. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc. 2007;13:653\u201363.","journal-title":"J Int Neuropsychol Soc"},{"key":"908_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2007.02.001","volume":"92","author":"M Kiang","year":"2007","unstructured":"Kiang M, Kutas M, Light GA, Braff DL. Electrophysiological insights into conceptual disorganization in schizophrenia. Schizophr Res. 2007;92:225\u201336.","journal-title":"Schizophr Res"},{"key":"908_CR35","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.clinph.2012.02.079","volume":"123","author":"AJ Rissling","year":"2012","unstructured":"Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, et al. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012;123:1942\u20139.","journal-title":"Clin Neurophysiol."},{"key":"908_CR36","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/npp.2017.25","volume":"42","author":"VB Perez","year":"2017","unstructured":"Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, et al. Mismatch negativity is a sensitive and predictive biomarker of perceptual learning during auditory cognitive training in schizophrenia. Neuropsychopharmacology. 2017;42:2206\u201313.","journal-title":"Neuropsychopharmacology."},{"key":"908_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijpsycho.2019.06.003","volume":"145","author":"VB Perez","year":"2019","unstructured":"Perez VB, Miyakoshi M, Makeig SD, Light GA. Mismatch negativity reveals plasticity in cortical dynamics after 1-hour of auditory training exercises. Int J Psychophysiol. 2019;145:40\u20137.","journal-title":"Int J Psychophysiol"},{"key":"908_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.schres.2019.11.015","volume":"215","author":"WC Hochberger","year":"2020","unstructured":"Hochberger WC, Thomas ML, Joshi YB, Molina J, Treichler EBH, Nungaray J, et al. Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients. Schizophr Res. 2020;215:97\u2013104.","journal-title":"Schizophr Res"},{"key":"908_CR39","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41386-018-0256-9","volume":"44","author":"WC Hochberger","year":"2019","unstructured":"Hochberger WC, Joshi YB, Thomas ML, Zhang W, Bismark AW, Treichler EBH, et al. Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. Neuropsychopharmacology. 2019;44:606\u201312.","journal-title":"Neuropsychopharmacology."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-020-00908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-020-00908-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-020-00908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:07:58Z","timestamp":1684616878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-00908-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1038\/s41386-020-00908-0","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}